JW Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company headquartered in Seoul, South Korea, focused on developing innovative therapeutics for central nervous system (CNS) disorders and other unmet medical needs. Founded in 1945, the company has evolved from a traditional pharmaceutical manufacturer into a modern biopharmaceutical company with a strong focus on neuroscience research and drug development.
The company is listed on the Korea Exchange (KRX: 001060) and has positioned itself as one of the leading Korean pharmaceutical companies in the CNS disorder space, with multiple programs targeting Alzheimer's disease, Parkinson's disease, and other neurological conditions.
| Attribute |
Details |
| Founded |
1945 |
| Headquarters |
Seoul, South Korea |
| Stock |
KRX: 001060 |
| CEO |
Lee Byeol-jun |
| Website |
jwpharma.co.kr |
| Employees |
2,000+ |
| Revenue |
~$500 million annually |
| Market |
Korea, global export |
Founded in 1945, JW Pharmaceutical has grown to become one of Korea's established pharmaceutical companies:
- 1945: Company founded as Korean pharmaceutical manufacturer
- 1990s: Expansion into CNS therapeutics
- 2000s: Development of proprietary drug delivery technologies
- 2010s: Active CNS pipeline development for neurodegeneration
- 2020s: Advanced clinical trials for PD and AD programs
JW Pharmaceutical manufactures and markets:
- Prescription medications
- Over-the-counter products
- Generic pharmaceuticals
- Biosimilars
¶ Research and Development
The company's R&D focus areas include:
- Novel small molecule therapeutics
- Biologics development
- Drug delivery systems
- Fixed-dose combinations
JW Pharmaceutical collaborates with:
- International pharmaceutical companies
- Academic institutions
- Contract research organizations
| Drug |
Mechanism |
Stage |
Status |
| JW-500 |
Dopamine receptor agonist |
Phase 2 |
Recruiting |
| JW-301 |
MAO-B inhibitor |
Preclinical |
Research |
| JW-703 |
Alpha-synuclein aggregation inhibitor |
Discovery |
Early research |
JW-500 is the company's lead Parkinson's disease program in Phase 2 clinical trials:
- Mechanism: Selective dopamine D2/D3 receptor agonist
- Indication: Motor symptoms in Parkinson's disease
- Differentiation: Targeting improved motor function with reduced side effects compared to existing agonists
The MAO-B inhibitor program aims to provide neuroprotective benefits:
- Mechanism: Selective MAO-B inhibition to reduce dopamine metabolism
- Rationale: Complementary to dopaminergic therapy
- Stage: Preclinical development
Early-stage program targeting the core pathology of Parkinson's disease:
- Target: Alpha-synuclein aggregation
- Mechanism: Small molecule inhibitor of oligomerization
- Rationale: Disease-modifying approach targeting Parkinson's progression
| Drug |
Mechanism |
Stage |
Status |
| JW-400 |
Beta-secretase (BACE) inhibitor |
Phase 1 |
Active |
| JW-502 |
Tau aggregation inhibitor |
Discovery |
Early research |
JW-400 targets amyloid-beta production through BACE inhibition:
Discovery-stage program targeting tau pathology:
- Target: Tau protein aggregation
- Mechanism: Prevent NFT formation
- Status: Early discovery
The company also has programs in:
- Depression and anxiety: Novel antidepressant candidates
- Epilepsy: Anti-convulsant therapies
- Rare neurological diseases: Orphan drug programs
JW Pharmaceutical focuses on:
- CNS Disorders: Parkinson's disease, Alzheimer's disease, depression
- Oncology: Novel anticancer agents
- Immunology: Autoimmune disease therapies
- Rare Diseases: Unmet medical needs in orphan diseases
- Cardiovascular: Cardiovascular therapeutics
- Medicinal chemistry
- In vitro pharmacology
- In vivo pharmacology
- ADMET screening
- Formulation development
- Central Research Institute in Seoul
- Korea University: CNS research collaboration
- Seoul National University: Drug discovery partnership
- Korea Institute of Science and Technology (KIST): Research collaboration
- Yonsei University: Clinical research partnerships
- International licensing agreements
- Co-development programs
- Contract manufacturing
- Clinical trial execution
- Drug commercialization
In South Korea, JW Pharmaceutical is recognized as:
- A leading CNS-focused pharmaceutical company
- A trusted brand among healthcare professionals
- A significant employer in the pharmaceutical sector
- Exports to multiple countries
- Global clinical trial participation
- International partnership agreements
- Export to Southeast Asia
- Licensing deals for international markets
South Korea has emerged as a significant player in global pharmaceutical development:
- Strong government support for biotech innovation
- World-class clinical trial infrastructure
- Growing number of innovative drug approvals
- Strong academic research foundation
Key competitors in the Korean CNS market:
- Samsung Bioepis
- Samsung BioLogics
- Celltrion
- Hanmi Pharmaceutical
- Daewoong Pharmaceutical
- LG Chem Life Sciences
South Korea represents a significant market for neurodegenerative disease therapeutics:
- Aging population: Increasing prevalence of AD and PD
- Regulatory environment: MFDS provides efficient approval pathway
- Research infrastructure: Strong academic institutions supporting drug discovery
- Manufacturing: Advanced pharmaceutical manufacturing capabilities